Chemotherapy Of Bacterial Infections

Experimental Chemotherapy, Volume II: Chemotherapy of Bacterial Infections: Part I is devoted to the history, development, and progress of experimental chemotherapy of bacterial infections. The subject matter has been arranged according to particular groups of compounds, and in a few instances according to specific diseases. The emphasis of Volume II is placed on synthetic compounds. The literature is covered up to the latter part of 1963. It is hoped that this volume will be found useful by investigators and teachers concerned with experimental work on new substances and by physicians and veterinarians who use them. The book opens with a discussion of chemotherapy with antibacterial dyestuffs. This is followed by separate chapters on the mode of action of antibacterial substances such as sulfonamides, penicillins, and other antibiotics; the main lines on which research into antibacterial drugs has developed; and drug resistance for chemotherapy. Subsequent chapters deal with antibacterial chemotherapy with sulfonamides, the experimental pharmacology and toxicology of sulfonamides, the use of nitrofurans as chemotherapeutic agents, and antibacterial agents of limited action. The final chapters discuss experimental chemotherapy of tuberculosis and leprosy.

Infections in Cancer Chemotherapy is a collection of paper that details the advancement in the understanding of infections in chemotherapy. The coverage of the text includes aggressive cancer treatment and its role in predisposing to infection; diagnosis of infection in patients with cancer; and non-bacterial infections associated with neoplastic disease. The selection also tackles the protocol for an international prospective trial of initial therapy regimens in neutropenic patients with malignant disease; and the use of gnotobiotics in hematology in improving acute leukemia treatment. The book will be of great interest to oncologists and hematologists.

The International Society of Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extension of chemotherapy into new areas. In some instances, expansion has been rapid, for example in cephalosporins, pen icillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, es pecially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is receiving increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tubercu losis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods. From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of cur rent progress in chemotherapy.

Preceded by: Antimicrobial chemotherapy / Roger Finch ... [et al.]. 6th ed. 2012.

The International Society of Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extension of chemotherapy into new areas. In some instances, expansion has been rapid, for example in cephalosporins, pen icillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, es pecially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is receiving increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tubercu losis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods. From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of cur rent progress in chemotherapy.

Well-respected and widely regarded as the most comprehensive text in the field, Antibiotic and Chemotherapy, 9th Edition by Drs. Finch, Greenwood, Whitley, and Norrby, provides globally relevant coverage of all types of antimicrobial agents used in human medicine, including all antiviral, antiprotozoan and anthelminthic agents. Comprehensively updated to include new FDA and EMEA regulations, this edition keeps you current with brand-new information about antiretroviral agents and HIV, superficial and mucocutaneous myscoses and systemic infections, management of the immunocompromised patient, treatment of antimicrobial resistance, plus coverage of new anti-sepsis agents and host/microbe modulators. Reference is easy thanks to a unique 3-part structure covering general aspects of treatment; reviews of every agent; and details of treatments of particular infections. Offer the best possible care and information to your patients about the increasing problem of multi-drug resistance and the wide range of new antiviral therapies now available for the treatment of HIV and other viral infections. Stay current with 21 new chapters including the latest information on superficial and mucocutaneous mycoses, systemic infections, anti-retroviral agents, and HIV. Get fresh perspectives and insights thanks to 21 newly-authored and extensively re-written chapters. Easily access information thanks to a unique 3-part structure covering general aspects of treatment; reviews of every agent; and details of treatments of particular infections. Apply the latest treatments for anti-microbial organisms such as MRSA, and multi-drug resistant forms of TB, malaria and gonorrhea. Keep up on the latest FDA and EMEA regulations.